11:01 AM EST - Neovasc Inc. : Today announced the submission of a Premarket Approval application to the U.S. Food and Drug Administration for its Neovasc Reducer™ medical device for the treatment of refractory angina. The submission also includes a request for an Advisory Panel meeting. Neovasc Inc.
shares T.NVCN are trading up $3.13 at $8.22.
